Company intelligence / Profile preview

Afecta Pharmaceuticals

Irvine, California, United Statesafectapharm.com ↗

Ownership: Private
Development stage: Phase 1

Overview

Afecta Pharmaceuticals develops precision medicines using AI-driven platforms targeting chronic diseases and cancers. Lead assets include small molecule drugs in early clinical stages across neurology, dermatology, oncology, and ophthalmology. The company has demonstrated bioactivity of its compounds in animal/tissue models and holds patents on novel anti-inflammatory pathways such as CCL5/RANTES inhibition. Some assets have been licensed to Supernus Pharmaceuticals.

Therapeutic areas: OncologyImmunologyDermatologyOphthalmologyNeurology
Modalities: Small moleculesChemical drugsNovel drug delivery technologies
Industry: Biotech

Drug pipeline

20 assets

AFX-5931

19 more assets in the full pipeline.

Partnerships

Supernus Pharmaceuticals Inc. (NASDAQ: SUPN)Allergan PLC/AbbVie Inc.LEO Pharma A/S

Beyond the preview

Go deeper on Afecta Pharmaceuticals.

Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from trial design and recruitment through results.

Trial phase
Status
Readouts

Licensing & deals

Explore licensing agreements, acquisitions, and the assets behind each deal.

Partners
Deal terms
Milestones

Funding history

Trace financing activity and the investors behind a company’s development.

Funding rounds
Investors
Capital raised

Competitive landscape

Compare peer pipelines by target, modality, and therapeutic area.

Peer companies
Targets
Pipeline overlap

Technologies & patents

Explore technology platforms and the patent landscape around relevant assets.

Platforms
Patents
Assignees

Research & analysis

Connect company news and source material to the questions you’re investigating.

Company news
Sources
Analysis

Bring the full picture into focus.

See how Gosset can support your research on Afecta Pharmaceuticals.